<DOC>
	<DOCNO>NCT01165983</DOCNO>
	<brief_summary>The purpose research study determine effect Aliskiren blood vessel blood flow . The primary hypothesis Aliskiren increase endothelial function 30 % comparison placebo group .</brief_summary>
	<brief_title>The Effect Aliskiren Endothelial Function Pre-Diabetes Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Group 1 . Subjects At Risk Developing Type 2 Diabetes INCLUSION CRITERIA 1 . Ages 2180 year 2 . Subjects `` risk '' develop type 2 Diabetes Mellitus ( First degree relatives history type 2 Diabetes Mellitus , History gestational Diabetes , Known impair glucose tolerance , Impaired fast plasma glucose 100126 mg/dl time enrollment ) EXCLUSION CRITERIA 1 . Treatment Aliskiren ( Tekturna ) 2 . Smokers ( use tobacco product previous 3 month ) 3 . Active Uncontrolled Cardiovascular Disease Myocardial infarction , angina within 12 month study participation Arrhythmia ( uncontrolled , highly symptomatic , require treatment lifethreatening ) CHF ( Class III IV symptom heart failure less ordinary exertion rest ) Stroke Transient Ischemic Attack ( TIA ) within 12 month study participation Uncontrolled Hypertension ( SBP &gt; 180 mmHg DBP &gt; 105 mmHg ; 2 abnormal reading visit ) History previous hypotensive episode 4 . Liver Disease ( AST , ALT , Alk Phos level &gt; 2x UNL ) 5 . Renal Disease ( creatinine &gt; 1.7 mg/dL woman &gt; 2.0 mg/dL men and/or estimate GFR &lt; 30 mL/min , history dialysis , nephrotic syndrome know renovascular hypertension ) time enrollment 6 . Hyperkalemia ( serum potassium &gt; 5.0 meq/L ) 7 . Severe Dyslipidemia ( TG &gt; 600 mg/dL Cholesterol &gt; 350 mg/dL ) 8 . Any Other Serious Chronic Disease Requiring Active Treatment 9 . Females Childbearing Potential Not Using Effective Form Birth Control Determined coinvestigators 10 . Pregnancy 11 . Taking Any Following Medications : Systemic ( inhale ) Glucocorticoids Antineoplastic Agents Cyclosporine , Ketoconazole , Furosemide , Warfarin Bronchodilators ( aminophyline , inhale beta agonist ) regular basis 12 . Patient known history immunodeficiency disease , include positive HIV ( ELISA Western blot ) and/or positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result past 13 . History drug alcohol abuse within 12months prior dose evidence abuse indicate laboratory assay conduct screen baseline evaluation Group 2 . Type 2 Diabetic Patients INCLUSION CRITERIA 1 . Ages 2180 year 2 . Type 2 Diabetes Mellitus stable expect change study period EXCLUSION CRITERIA 1 . Treatment Aliskiren ( Tekturna ) 2 . Smokers ( use tobacco product previous 3 month ) 3 . Active Uncontrolled Cardiovascular Disease Myocardial infarction , angina within 12 month study participation Arrhythmia ( uncontrolled , highly symptomatic , require treatment lifethreatening ) CHF ( Class III IV symptom heart failure less ordinary exertion rest ) Stroke Transient Ischemic Attack ( TIA ) within 12 month study participation Uncontrolled Hypertension ( SBP &gt; 180 mmHg DBP &gt; 105 mmHg ; 2 abnormal reading visit ) History previous hypotensive episode 4 . Liver Disease ( AST , ALT , Alk Phos level &gt; 2x UNL ) 5 . Renal Disease ( creatinine &gt; 1.7 mg/dL woman &gt; 2.0 mg/dL men and/or estimate GFR &lt; 30 mL/min , history dialysis , nephrotic syndrome know renovascular hypertension ) time enrollment 6 . Hyperkalemia ( serum potassium &gt; 5.0 meq/L ) 7 . Severe Dyslipidemia ( TG &gt; 600 mg/dL Cholesterol &gt; 350 mg/dL ) 8 . Any Other Serious Chronic Disease Requiring Active Treatment 9 . Females Childbearing Potential Not Using Effective Form Birth Control Determined coinvestigators 10 . Pregnancy 11 . Taking Any Following Medications : Systemic ( inhale ) Glucocorticoids Antineoplastic Agents Cyclosporine , Ketoconazole , Furosemide , Warfarin Bronchodilators ( aminophyline , inhale beta agonist ) regular basis 12 . Patient known history immunodeficiency disease , include positive HIV ( ELISA Western blot ) and/or positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result past 13 . History drug alcohol abuse within 12months prior dose evidence abuse indicate laboratory assay conduct screen baseline evaluation 14 . Severe proliferative retinopathy render subject legally blind 15 . Previous diagnosis severe gastroparesis diabeticorum due autonomic neuropathy necessitate hospital admission 16 . Presence nonhealing foot ulceration due severe peripheral diabetic neuropathy 17 . Documented diabetic nephropathy manifest macroalbuminuria , ( 2 3 urine specimen collect within 36 month period urine albumin &gt; 300 ug/mg creatinine</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>